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tive was to determine the impact of the PDL on net costs and
utilization of LANA, total narcotic analgesics, and non-narcotic
substitute drugs. METHODS: We obtained Arkansas Medicaid
claims data from January 2003 to July 2007. Net costs based on
CMS-rebates and mg of morphine equivalents (MEq) obtained
from standardized conversion tables were the primary outcome
variables. Autoregressive-integrated-moving-average ARIMA
time series models of monthly measures were estimated. Inter-
rupted OLS time series models were estimated to capture the
impact of the policy on the shifts in trend and intercept.
RESULTS: There were 709,791 Medicaid eligibles, of which
3,227 used a LANA whom had an average age of 44.65 years,
39.36% male, and 80.54% white. The PDL was associated with
a $1.41 million (95%CI: $0.37–$2.43 million) and a $1.78
million (95%CI: $0.48–$3.05 million) cost reduction for LANA
and total narcotic analgesics over the 22-month post-policy
period. Total narcotic utilization was not signiﬁcantly different
than trend utilization for 18 months of the post-policy period.
The PDL was associated with a signiﬁcant increase in C-II short-
acting narcotic utilization of 202,828 (95%CI: 68,160–337,497)
MEq and non-signiﬁcant decreases in C-II LANA and CIII-V
narcotic utilization. A sensitivity analysis with a term to capture
the effect of generic fentanyl availability yielded more conserva-
tive cost saving estimates. There was no PDL-related increase
in the utilization of benzodiazepines, migraine agents, NSAIDs,
muscle-relaxants, anticonvulsants, or antidepressants. CON-
CLUSIONS: The PDL resulted in signiﬁcant cost savings for
narcotic analgesics. The policy did not consistently affect the
overall level of narcotic analgesia prescribed, however, the policy
may have steered patients toward shorter acting narcotics.
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OBJECTIVES: To evaluate health care resource use, costs and
patient-reported outcomes (PRO’s) among patients with neuro-
pathic pain, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups in Germany. METHODS: Patients were
consecutively recruited by physicians in general practice (n = 47)
in 2005. Data on resource utilization due to neuropathic pain
was collected retrospectively for six months. Costs were esti-
mated from the societal perspective. PRO were assessed through
generic SF-36 and disease-speciﬁc von Korff Index, and Patient
Health Questionnaire Depression (PHQ-D) questionnaires at
time of recruitment. Groups were compared using multivariable
general linear modeling (GLM). RESULTS: Ninety-nine patients
took part in this study (n = 44 self-treatment, n = 23 guideline,
n = 32 non-guideline-groups). The majority of patients were
overweight, 61% of all patients were women, and 29% were
currently employed. Average duration of neuropathic pain was
about 6.2 years and was comparable among the groups. Patients
in the self-treatment-group were younger than patients in guide-
line or non-guideline-group (mean age 54.5 vs. 67.6 vs. 66.9
years, p < 0.0001). Mean total costs per patient and 6 months
were €674.23 [95%CI 225.95; 1122.51] vs. €1507.21 [95%CI
715.48; 2298.94] vs. €1426.24[95%CI 850.18; 2002.30] (self-
treatment-vs. guideline vs. non-guideline-group, respectively,
p = 0.0092, by GLM adjusted by age and BMI). PRO as evalu-
ated by von Korff Index and PHQ-D were better in the self-
treatment-group patients. The groups did not differ in the mean
component scores of SF-36. CONCLUSIONS: Patients in self-
treatment-group in this study had the lowest societal mean total
costs per patient and better PRO’s (as evaluated by von Korff
Index and PHQ-D) compared to other groups. No major differ-
ences were detected between guideline and non-guideline
patients.
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OBJECTIVES: To assess PRO and costs in German patients with
back pain, speciﬁcally for guideline, non-guideline, and self-
treatment-groups. METHODS: Patients (n = 145) were recruited
by physicians in general practice (n = 54) in 2005. Resource
utilization data due to back pain was collected retrospectively
for six months. Patients completed the generic SF-36, and
the disease-speciﬁc Hannover Functional Questionnaire (FFbH),
von Korff Index and Patient Health Questionnaire Depression
(PHQ-D) forms at the time of enrollment. Groups were com-
pared using multivariable general linear modeling (GLM).
RESULTS: Patients (n = 72 self-treatment, n = 29 guideline-,
n = 44 non-guideline-groups) were on average 54 years old,
64% of them were women. Patients with self-treatment were
younger, more likely to be employed and had lower BMI than
patients in guideline or non-guideline-group (mean age 49.8 vs.
59.4 vs. 57.4 years; mean BMI 24.9 vs. 28.2 vs. 26.8). Average
duration of back pain was about 7.3 years and was comparable
among the groups. The groups differed regarding the SF-36, the
von Korff index, FFbH-R and frequency of PHQ-D somatoform
symptoms. The self-treatment group reported the highest mean
physical component of the SF-36 compared to other groups
(39.6  10.4, p = 0.0011, adjusted by age). Mean total societal
perspective costs per patient were (€417.61 [95%CI 171.03;
664.18] vs. €3159.17 [95%CI 933.62; 5384.73] vs. €1640.58
[95%CI 818.02; 2463.13], self-treatment-vs. guideline vs. non-
guideline-group, respectively). The major cost factors were: in
the self-treatment-group, reduction of earning capacity (43.4%),
sport activities (26.9%), and remedies (19.3%); in the guideline-
group, sick leaves (64.0%), prescribed medications (10.1%), and
visits to physicians (6.2%); and in the non-guideline-group,
sick leaves (23.8%), remedies (20.7%), and reduction of earn-
ing capacity (12.7%). CONCLUSIONS: PRO seem to be better
and costs lower in self-treatment-group. The major cost
factors are different among guideline, non-guideline and self-
treatment-groups, while costs are positively related to age and
unemployment.
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OBJECTIVES: Renal impairment after transplant is associated
to a greater risk of death. It is of interest to asses how and when
the diagnosis is made. To evaluate the diagnostic method of renal
dysfunction (Clinical or Histological). METHODS: Observa-
tional and multicenter study including 872 renal transplant
patients with at least two years post-transplant. Data were ret-
rospectively collected at ﬁve time pointssince transplant. Clini-
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